CDM Tools
Please note: these resources have not been tested locally using robust QI methodology to ensure no unintended adverse outcomes
We strongly recommend use using a QI approach when adopting any of these resources. You can find QI tool and templates here.
UCL Partners - Search and risk stratification tools
“We have developed defined search and stratification tools to help primary care teams identify people with long term conditions. These tools can be adapted to meet local preference if required. These tools stratify patients into low, medium and high risk of deterioration.
These easy-to-deploy tools have been designed for the management of patients with Asthma, COPD, Type 2 Diabetes and Hypertension. All tools have been developed by our clinical team, working with the Clinical Effectiveness Group based at Queen Mary University of London. The search criteria used draws on national guidance.”
UCL Partners Primary Care Innovation Team
Click the link above to read more about the benefits of UCL long term condition support.
The Patient Activation Measure (PAM)
The PAM ® is an assessment tool used to quantify and understand a person’s ability to manage their own care. It helps to support decision making for what steps are required to increase a person’s knowledge, skills and confidence to improve health and wellbeing outcomes. This tool is validated for use in England and is a licensed tool.
Click the button for more information regarding current research on the PAM ®
To find out more about the use of PAM® in NHS Lothian contact Leonie Hunter
Mapmydiabetes: an online resource to enhance self-management
MyCOPD
The technology described in this briefing is myCOPD. It helps people with chronic obstructive pulmonary disease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals care for people with COPD.
The innovative aspect is that it allows for care (such as pulmonary rehabilitation) to be provided remotely, based on a person's self-assessed needs. It can also help people with COPD to manage their condition at home where services are limited because of COVID-19.
The intended place in therapy would be as part of self-management for people as an alternative to some routine healthcare visits such as pulmonary rehabilitation.
The main points from the evidence summarised in this briefing are from 2 randomised controlled trials and 1 observational study, covering a total of 167 people with COPD. They show that myCOPD is associated with reduced COPD symptom severity and improved inhaler technique.
Key uncertainties are that the quantity and quality of evidence for myCOPD is limited. None of the studies followed up participants for longer than 3 months, so there is no medium- or longterm evidence. All studies had relatively few participants (fewer than 100), and had limited power to detect statistical differences between treatment groups.
The cost of myCOPD is £40 per person (excluding VAT).